HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPS...

by D.S. Siegel, K. Weisel, A. Zahlten-Kumeli, R. Medhekar, S. Sapra, B. Ding, X. Leleu
Published 2020-11-01

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER...

by H. Quach, A. Nooka, O. Samoylova, C.P. Venner, T. Facon, A. Spencer, S.Z. Usmani, K. Weisel, M. Mateos, K. Kim, S. Grosicki, K. Suzuki, S. Delimpasi, M. Obreja, A. Zahlten-Kumeli
Published 2020-11-01